Amir Aboofazeli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amir Aboofazeli has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Arash Letafati
Research Center for Clinical Virology Tehran University of Medical Sciences Tehran Iran
3 shared publications Ahmadreza Sadeghi
2 shared publicationsRoben Soheili
Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran
2 shared publicationsSheida Sarrafzadeh
Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications- Sheida Sarrafzadeh
Department of Epidemiology and Biostatistics, School of Health, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Zahra Sadeghi
Department of Pathobiology, Division of Microbiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Molecular epidemiology and genotype distribution of human papillomavirus in Iran: A nationwide retrospective study of over 100,000 referred individuals
Background and aim: Human papillomavirus (HPV) infection is a major public health challenge worldwide, especially in developing countries. This study assessed the nationwide molecular epidemiology and HPV genotype distribution in Iran to optimize public screening and Further strategies for vaccination in the country. Materials and methods: We conducted a nationwide multicenter retrospective observational study using HPV genotyping records obtained from participating laboratories across Iran between 2015 and 2024. Prevalence estimates, genotype distributions, and temporal trends were evaluated. Data were assessed for age, sex, and time trends using descriptive statistics and generalized linear models and were analyzed using R software. Results: The overall HPV prevalence in this group was 34.7%, with 56.7% of positive cases having at least one high-risk (HR) genotype. Men showed a significantly higher overall prevalence compared to women (44.4% vs. 34.1%, p < 0.001), although women had a higher proportion of HR-HPV among positive cases (59.2% vs. 35.6%). Over time, the overall HPV positivity rate increased by 7% per year from 2015 to 2024, whereas the proportion of HR-HPV among infected individuals decreased by 23% per year, reflecting an increase in low-risk strains such as HPV-6. Although HPV-16 was the predominant HR genotype (26.5% of HR cases), 77.7% of all HR-positive individuals carried non-16/18 carcinogenic strains of HPV. Conclusion: The epidemiological profile of HPV in Iran is evolving, characterized by an increase in overall prevalence and a predominant presence of non-16/18 HR genotypes. The significant burden of diverse carcinogenic strains highlights the limitations of exclusive bivalent or quadrivalent vaccination and standard 16/18-axis screening. The implementation of gender-neutral 9-valent vaccination programs with an emphasis on men and the expansion of routine diagnostic coverage to multiple molecular platforms are recommended as critical requirements for effective cancer prevention in Iran.
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMolecular epidemiology and genotype distribution of human papillomavirus in Iran: A nationwide retrospective study of over 100,000 referred individuals
Background and aim: Human papillomavirus (HPV) infection is a major public health challenge worldwide, especially in developing countries. This study assessed the nationwide molecular epidemiology and HPV genotype distribution in Iran to optimize public screening and Further strategies for vaccination in the country. Materials and methods: We conducted a nationwide multicenter retrospective observational study using HPV genotyping records obtained from participating laboratories across Iran between 2015 and 2024. Prevalence estimates, genotype distributions, and temporal trends were evaluated. Data were assessed for age, sex, and time trends using descriptive statistics and generalized linear models and were analyzed using R software. Results: The overall HPV prevalence in this group was 34.7%, with 56.7% of positive cases having at least one high-risk (HR) genotype. Men showed a significantly higher overall prevalence compared to women (44.4% vs. 34.1%, p < 0.001), although women had a higher proportion of HR-HPV among positive cases (59.2% vs. 35.6%). Over time, the overall HPV positivity rate increased by 7% per year from 2015 to 2024, whereas the proportion of HR-HPV among infected individuals decreased by 23% per year, reflecting an increase in low-risk strains such as HPV-6. Although HPV-16 was the predominant HR genotype (26.5% of HR cases), 77.7% of all HR-positive individuals carried non-16/18 carcinogenic strains of HPV. Conclusion: The epidemiological profile of HPV in Iran is evolving, characterized by an increase in overall prevalence and a predominant presence of non-16/18 HR genotypes. The significant burden of diverse carcinogenic strains highlights the limitations of exclusive bivalent or quadrivalent vaccination and standard 16/18-axis screening. The implementation of gender-neutral 9-valent vaccination programs with an emphasis on men and the expansion of routine diagnostic coverage to multiple molecular platforms are recommended as critical requirements for effective cancer prevention in Iran.
- Open Access
- 31 July 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 1-8
Investigating the link between HPV genotypes and cervical abnormality incidence in women with HPV infections: insights from a leading referral centre
Cervical cancer (CC) is a serious health issue, especially in low- and middle-income countries, primarily caused by human papillomavirus (HPV) infection, particularly genotypes 16 and 18. Other risk factors include smoking, early sexual activity, and long-term oral contraceptive use. Early detection through cervical cytology and HPV testing is vital for effective prevention. This study aimed to analyze the clinical and epidemiological characteristics of cervical intraepithelial neoplasia (CIN) in HPV-positive women at a Tehran teaching hospital, focusing on HPV genotypes and their association with CIN. We conducted a cross-sectional study of HPV-positive women who underwent Pap smear testing, HPV genotyping via real-time PCR, and colposcopy with biopsies of suspected lesions. Risk factors like smoking and alcohol consumption were evaluated, and statistical analyses were performed, including ordinal logistic regression. Among participants, 52.4% had abnormal CIN: CIN I (31.1%), CIN II (11.4%), and CIN III (10.0%). HPV-16 was the most prevalent genotype (43.7%), significantly associated with severe CIN outcomes (odds ratio [OR] = 2.88, 95% CI), followed by HPV-18 (OR = 1.87, 95% CI). Smoking increased the risk of severe CIN (OR = 1.53, 95% CI), while older age and later age at sexual debut correlated with better CIN outcomes. HPV-16 and smoking are major predictors of severe CIN, highlighting the need for targeted interventions such as HPV vaccination and smoking cessation, along with regular screenings to lower cervical cancer risks. Additional research is required to evaluate the persistence of different HPV genotypes and their progression to CIN and cervical cancer.”
- 31 July 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 1-8
Open AccessInvestigating the link between HPV genotypes and cervical abnormality incidence in women with HPV infections: insights from a leading referral centre
Cervical cancer (CC) is a serious health issue, especially in low- and middle-income countries, primarily caused by human papillomavirus (HPV) infection, particularly genotypes 16 and 18. Other risk factors include smoking, early sexual activity, and long-term oral contraceptive use. Early detection through cervical cytology and HPV testing is vital for effective prevention. This study aimed to analyze the clinical and epidemiological characteristics of cervical intraepithelial neoplasia (CIN) in HPV-positive women at a Tehran teaching hospital, focusing on HPV genotypes and their association with CIN. We conducted a cross-sectional study of HPV-positive women who underwent Pap smear testing, HPV genotyping via real-time PCR, and colposcopy with biopsies of suspected lesions. Risk factors like smoking and alcohol consumption were evaluated, and statistical analyses were performed, including ordinal logistic regression. Among participants, 52.4% had abnormal CIN: CIN I (31.1%), CIN II (11.4%), and CIN III (10.0%). HPV-16 was the most prevalent genotype (43.7%), significantly associated with severe CIN outcomes (odds ratio [OR] = 2.88, 95% CI), followed by HPV-18 (OR = 1.87, 95% CI). Smoking increased the risk of severe CIN (OR = 1.53, 95% CI), while older age and later age at sexual debut correlated with better CIN outcomes. HPV-16 and smoking are major predictors of severe CIN, highlighting the need for targeted interventions such as HPV vaccination and smoking cessation, along with regular screenings to lower cervical cancer risks. Additional research is required to evaluate the persistence of different HPV genotypes and their progression to CIN and cervical cancer.”
- Open Access
- 9 March 2024
- Published by Brieflands in Archives of Neuroscience
- Vol. 11 (2)
Distinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a virus in the coronaviridae, has caused a global pandemic with various symptoms and complications. Among the groups affected by this virus are individuals with multiple sclerosis (MS), a chronic autoimmune disorder that affects the primary central nervous system (CNS). Understanding coronavirus disease 2019’s (COVID-19) impact on MS patients is crucial for optimizing patient management and developing targeted therapies due to the challenges it presents. Objectives: The primary purpose of this study was to investigate the respiratory and neurology symptoms of COVID-19 in patients with MS in comparison to the non-infected group. Furthermore, this study examined how age and gender might affect the symptoms of contracting COVID-19 and the mortality rate in patients with MS. Methods: The data were collected from six hospitals within the Iranian Network for Research in Viral Diseases (INRVD) between March 2020 and July 2021. A total of 63 individuals diagnosed with MS were examined, with 30 testing positive for both COVID-19 and MS; however, 33 individuals were positive only for MS. These individuals had presented at the hospital experiencing respiratory symptoms, including rhinorrhea, difficulty breathing, and cough. Various clinical aspects were evaluated, including age, gender, and the presence of COVID-19 symptoms. Statistical analyses included the Mann-Whitney t-test, Fisher’s exact test, and odds ratio calculations using SPSS-27 and R 4.2.3. Results: The study encompassed 63 MS patients, with 29 (46%) and 34 (54%) males and females, respectively. Of these patients, 30 individuals were positive for COVID-19. Most subjects were from Tehran province, Iran. Patients in the case group were significantly younger than those in the control group. Notably, dizziness, breath shortness, and vomiting were significantly more prevalent in MS patients following COVID-19. Conclusions: This study highlights the distinct clinical presentation of COVID-19 in individuals with MS. Dizziness, breath shortness, vomiting, and increased mortality were significantly associated with MS patients with COVID-19. The aforementioned findings underscore the importance of tailored management strategies for this unique patient population following the disease.
- 9 March 2024
- Published by Brieflands in Archives of Neuroscience
- Vol. 11 (2)
Open AccessDistinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a virus in the coronaviridae, has caused a global pandemic with various symptoms and complications. Among the groups affected by this virus are individuals with multiple sclerosis (MS), a chronic autoimmune disorder that affects the primary central nervous system (CNS). Understanding coronavirus disease 2019’s (COVID-19) impact on MS patients is crucial for optimizing patient management and developing targeted therapies due to the challenges it presents. Objectives: The primary purpose of this study was to investigate the respiratory and neurology symptoms of COVID-19 in patients with MS in comparison to the non-infected group. Furthermore, this study examined how age and gender might affect the symptoms of contracting COVID-19 and the mortality rate in patients with MS. Methods: The data were collected from six hospitals within the Iranian Network for Research in Viral Diseases (INRVD) between March 2020 and July 2021. A total of 63 individuals diagnosed with MS were examined, with 30 testing positive for both COVID-19 and MS; however, 33 individuals were positive only for MS. These individuals had presented at the hospital experiencing respiratory symptoms, including rhinorrhea, difficulty breathing, and cough. Various clinical aspects were evaluated, including age, gender, and the presence of COVID-19 symptoms. Statistical analyses included the Mann-Whitney t-test, Fisher’s exact test, and odds ratio calculations using SPSS-27 and R 4.2.3. Results: The study encompassed 63 MS patients, with 29 (46%) and 34 (54%) males and females, respectively. Of these patients, 30 individuals were positive for COVID-19. Most subjects were from Tehran province, Iran. Patients in the case group were significantly younger than those in the control group. Notably, dizziness, breath shortness, and vomiting were significantly more prevalent in MS patients following COVID-19. Conclusions: This study highlights the distinct clinical presentation of COVID-19 in individuals with MS. Dizziness, breath shortness, vomiting, and increased mortality were significantly associated with MS patients with COVID-19. The aforementioned findings underscore the importance of tailored management strategies for this unique patient population following the disease.
- Open Access
- 12 December 2023
- Published by Brieflands in Archives of Neuroscience
- Vol. 10 (4)
A Survey on Respiratory and Neurological Symptoms in Alzheimer’s, Schizophrenia, Bipolar, and Migraine Patients Following COVID-19 Infection
Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 led to the global coronavirus disease 2019 (COVID-19) pandemic with a wide range of clinical symptoms. Neurological complications have been a significant concern, with diverse symptoms and potential neuroinvasive mechanisms. The pandemic has also impacted individuals with mental health conditions, such as migraines, bipolar disorder (BD), and schizophrenia, highlighting the complex interconnections between physical and mental health during these challenging times. Objectives: This retrospective report from the Iranian Network for Research in Viral Diseases (INRVD) study aimed to investigate the multifaceted interactions between COVID-19, neurological complications, and mental health disorders (e.g., migraines, BD, and schizophrenia) to better understand their collective impact on individuals’ health and well-being. Methods: This study involved 63 individuals who tested positive for COVID-19, including 32 females (50.8%) and 31 males (49.2%). The participants were categorized into different groups based on their underlying conditions: 7 individuals with schizophrenia, 8 with BD, 6 with migraines, 12 with Alzheimer's disease, and 30 with COVID-19 without any underlying neurologic disorder. This investigation was carried out in 12 hospitals supervised by the INRVD between March 2020 and May 2021. The study used frequencies and percentages to describe the data and employed chi-square tests, including the contingency coefficient, to explore associations between COVID-19 symptoms and disease groups. Results: The analysis of clinical manifestations revealed distinctive patterns. Cough was the most prevalent symptom across the entire sample, affecting over 79% of participants. Fever followed as the second most common symptom, with approximately 62% of individuals reporting it. Fatigue ranked third, impacting 57% of the subjects. In contrast, vomiting was the least frequently reported symptom, with an incidence of only 14.3%. In terms of specific conditions, a notable discrepancy was observed in the prevalence of headaches. Although present in 71.4% of individuals with schizophrenia, this symptom was reported by only 50% of those with BD, followed by 66.7% with migraines and 83.3% with Alzheimer’s. The patients without neurologic disorders exhibited a lower incidence of neurological manifestations, with only 23.3% reporting headaches. Conclusions: This study provides insights into the clinical manifestations of COVID-19 in individuals with distinct underlying conditions. The prevalence and presentation of symptoms varied significantly across the different groups, and neurological symptoms exhibited a higher prevalence in this patient group than those without any underlying neurologic disorders. This study aimed for a more comprehensive understanding of the probable intricate interplay between COVID-19, underlying health conditions, and clinical manifestations. Understanding these differences is crucial for tailoring effective clinical interventions.
- 12 December 2023
- Published by Brieflands in Archives of Neuroscience
- Vol. 10 (4)
Open AccessA Survey on Respiratory and Neurological Symptoms in Alzheimer’s, Schizophrenia, Bipolar, and Migraine Patients Following COVID-19 Infection
Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 led to the global coronavirus disease 2019 (COVID-19) pandemic with a wide range of clinical symptoms. Neurological complications have been a significant concern, with diverse symptoms and potential neuroinvasive mechanisms. The pandemic has also impacted individuals with mental health conditions, such as migraines, bipolar disorder (BD), and schizophrenia, highlighting the complex interconnections between physical and mental health during these challenging times. Objectives: This retrospective report from the Iranian Network for Research in Viral Diseases (INRVD) study aimed to investigate the multifaceted interactions between COVID-19, neurological complications, and mental health disorders (e.g., migraines, BD, and schizophrenia) to better understand their collective impact on individuals’ health and well-being. Methods: This study involved 63 individuals who tested positive for COVID-19, including 32 females (50.8%) and 31 males (49.2%). The participants were categorized into different groups based on their underlying conditions: 7 individuals with schizophrenia, 8 with BD, 6 with migraines, 12 with Alzheimer's disease, and 30 with COVID-19 without any underlying neurologic disorder. This investigation was carried out in 12 hospitals supervised by the INRVD between March 2020 and May 2021. The study used frequencies and percentages to describe the data and employed chi-square tests, including the contingency coefficient, to explore associations between COVID-19 symptoms and disease groups. Results: The analysis of clinical manifestations revealed distinctive patterns. Cough was the most prevalent symptom across the entire sample, affecting over 79% of participants. Fever followed as the second most common symptom, with approximately 62% of individuals reporting it. Fatigue ranked third, impacting 57% of the subjects. In contrast, vomiting was the least frequently reported symptom, with an incidence of only 14.3%. In terms of specific conditions, a notable discrepancy was observed in the prevalence of headaches. Although present in 71.4% of individuals with schizophrenia, this symptom was reported by only 50% of those with BD, followed by 66.7% with migraines and 83.3% with Alzheimer’s. The patients without neurologic disorders exhibited a lower incidence of neurological manifestations, with only 23.3% reporting headaches. Conclusions: This study provides insights into the clinical manifestations of COVID-19 in individuals with distinct underlying conditions. The prevalence and presentation of symptoms varied significantly across the different groups, and neurological symptoms exhibited a higher prevalence in this patient group than those without any underlying neurologic disorders. This study aimed for a more comprehensive understanding of the probable intricate interplay between COVID-19, underlying health conditions, and clinical manifestations. Understanding these differences is crucial for tailoring effective clinical interventions.
- 29 July 2023
- Published by Maad Rayan Publishing Company in International Journal of Enteric Pathogens
- Vol. 11 (3) , 108-115
Unveiling the Impact of Homogenous Vaccines on Clinical Symptoms and Risk Factors Following the SARS-CoV-2 Infection
Background: The COVID-19 pandemic is significant due to its global impact on public health and life situations. It has led to widespread infections and strained healthcare systems, causing significant loss of life. The pandemic has underscored the urgent need for effective measures to control its spread and protect communities worldwide. Objectives: The main goal of this research was to evaluate the clinical symptoms, risk factors, and manifestations linked to COVID-19 among the vaccinated healthcare worker (HCW) population under study. Materials and Methods: The study population comprised HCWs with respiratory symptoms who received three doses of vaccination homogeneously. Real-time polymerase chain reaction (RT-PCR) testing was conducted on nasopharyngeal and nasal swab samples using a one-step RT-PCR. The enzyme-linked immunosorbent assay also evaluated immunoglobulin G antibody levels. Results: Among the most commonly reported symptoms, general fatigue, fever, and cough were the most prevalent, divided by vaccine type. Furthermore, among the associated risk factors, concerns about transmission to other family members, anxiety, and depression were found to be prominent. Conclusion: The study findings highlight that the vaccine type is associated with clinical manifestations. Additionally, the result reveals the significant contribution of occupational roles to the experiences of HCWs during the COVID-19 pandemic. The findings emphasize the need for tailored support systems to address the diverse challenges faced by HCWs, such as concerns about transmission, anxiety, and occupational stress.
- 29 July 2023
- Published by Maad Rayan Publishing Company in International Journal of Enteric Pathogens
- Vol. 11 (3) , 108-115
Unveiling the Impact of Homogenous Vaccines on Clinical Symptoms and Risk Factors Following the SARS-CoV-2 Infection
Background: The COVID-19 pandemic is significant due to its global impact on public health and life situations. It has led to widespread infections and strained healthcare systems, causing significant loss of life. The pandemic has underscored the urgent need for effective measures to control its spread and protect communities worldwide. Objectives: The main goal of this research was to evaluate the clinical symptoms, risk factors, and manifestations linked to COVID-19 among the vaccinated healthcare worker (HCW) population under study. Materials and Methods: The study population comprised HCWs with respiratory symptoms who received three doses of vaccination homogeneously. Real-time polymerase chain reaction (RT-PCR) testing was conducted on nasopharyngeal and nasal swab samples using a one-step RT-PCR. The enzyme-linked immunosorbent assay also evaluated immunoglobulin G antibody levels. Results: Among the most commonly reported symptoms, general fatigue, fever, and cough were the most prevalent, divided by vaccine type. Furthermore, among the associated risk factors, concerns about transmission to other family members, anxiety, and depression were found to be prominent. Conclusion: The study findings highlight that the vaccine type is associated with clinical manifestations. Additionally, the result reveals the significant contribution of occupational roles to the experiences of HCWs during the COVID-19 pandemic. The findings emphasize the need for tailored support systems to address the diverse challenges faced by HCWs, such as concerns about transmission, anxiety, and occupational stress.